BIOCIENCIAS: Bª Y CLÍNICA DEL CÁNCER Y MEDIC. TRASLACIONAL
Doktorego eskola
University of Milano-Bicocca
Milán, ItaliaUniversity of Milano-Bicocca-ko ikertzaileekin lankidetzan egindako argitalpenak (21)
2024
-
Comparison between tofacitinib and ustekinumab as a third-line therapy in refractory ulcerative colitis: A multicenter international study
United European Gastroenterology Journal
-
Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022
eClinicalMedicine, Vol. 71
-
Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey
Infection
-
Phenotypic profiling of CD34+ cells by advanced flow cytometry improves diagnosis of juvenile myelomonocytic leukemia
Haematologica, Vol. 109, Núm. 2, pp. 521-532
-
Survival in multiple myeloma and SARS-COV-2 infection through the COVID-19 pandemic: Results from the EPICOVIDEHA registry
Hematological Oncology, Vol. 42, Núm. 1
2023
-
Age, successive waves, immunization, and mortality in elderly COVID-19 hematological patients: EPICOVIDEHA findings
International Journal of Infectious Diseases, Vol. 137, pp. 98-110
-
COVID-19 in adult acute myeloid leukemia patients: a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA)
Haematologica, Vol. 108, Núm. 1, pp. 22-33
-
Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance
Nature Communications, Vol. 14, Núm. 1
2022
-
B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA)
Frontiers in Oncology, Vol. 12
-
Bone Marrow Stromal Cell Regeneration Profile in Treated B-Cell Precursor Acute Lymphoblastic Leukemia Patients: Association with MRD Status and Patient Outcome
Cancers, Vol. 14, Núm. 13
-
Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey
Blood, Vol. 140, Núm. 26, pp. 2773-2787
-
Flow cytometric minimal residual disease assessment in B-cell precursor acute lymphoblastic leukaemia patients treated with CD19-targeted therapies — a EuroFlow study
British Journal of Haematology, Vol. 197, Núm. 1, pp. 76-81
2021
-
Automated identification of leukocyte subsets improves standardization of database-guided expert-supervised diagnostic orientation in acute leukemia: a EuroFlow study
Modern Pathology, Vol. 34, Núm. 1, pp. 59-69
-
COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)
Journal of Hematology and Oncology, Vol. 14, Núm. 1
2020
-
Inhibition of inflammatory signaling in Pax5 mutant cells mitigates B-cell leukemogenesis
Scientific Reports, Vol. 10, Núm. 1
2019
-
Differential expression of CD73, CD86 and CD304 in normal vs. leukemic B-cell precursors and their utility as stable minimal residual disease markers in childhood B-cell precursor acute lymphoblastic leukemia
Journal of Immunological Methods, Vol. 475
-
Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition)
European Journal of Immunology, Vol. 49, Núm. 10, pp. 1457-1973
2018
-
Automated database-guided expert-supervised orientation for immunophenotypic diagnosis and classification of acute leukemia
Leukemia, Vol. 32, Núm. 4, pp. 874-881
2017
-
Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia
Blood, Vol. 129, Núm. 3, pp. 347-357
2015
-
Quality assessment program for EuroFlow protocols: Summary results of four-year (2010-2013) quality assurance rounds
Cytometry Part A, Vol. 87, Núm. 2, pp. 145-156